169 related articles for article (PubMed ID: 12813448)
1. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study.
Blum W; Khoury H; Lin HS; Vij R; Goodnough LT; Devine S; Dipersio J; Adkins D
Biol Blood Marrow Transplant; 2003 Jun; 9(6):397-404. PubMed ID: 12813448
[TBL] [Abstract][Full Text] [Related]
2. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
4. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
[TBL] [Abstract][Full Text] [Related]
5. Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity.
Blum W; Brown R; Lin HS; Zehnbauer B; Khoury H; Goodnough LT; Westervelt P; Vij R; DiPersio J; Adkins D
Biol Blood Marrow Transplant; 2002; 8(11):608-18. PubMed ID: 12463480
[TBL] [Abstract][Full Text] [Related]
6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
7. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
8. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.
Deeg HJ; Amylon ID; Harris RE; Collins R; Beatty PG; Feig S; Ramsay N; Territo M; Khan SP; Pamphilon D; Leis JF; Burdach S; Anasetti C; Hackman R; Storer B; Mueller B
Biol Blood Marrow Transplant; 2001; 7(4):208-15. PubMed ID: 11349807
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.
Khoury H; Adkins D; Brown R; Pence H; Vij R; Goodnough LT; Westervelt P; Trinkaus K; Lin HS; DiPersio Y
Biol Blood Marrow Transplant; 2001; 7(6):352-8. PubMed ID: 11464978
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy.
McAfee SL; Powell SN; Colby C; Spitzer TR
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):151-6. PubMed ID: 12007954
[TBL] [Abstract][Full Text] [Related]
11. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
17. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S; Lin HS; Dipersio J; Adkins D
Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
[TBL] [Abstract][Full Text] [Related]
19. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
20. CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.
Maeda S; Kagami Y; Ogura M; Taji H; Suzuki R; Kondo E; Asakura S; Takeuchi T; Miura K; Ando M; Nakamura S; Ito T; Kinoshita T; Ueda R; Morishima Y
Int J Hematol; 2001 Aug; 74(2):214-21. PubMed ID: 11594525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
